NASDAQ · PALI
Healthcare · Biotechnology
$2.05
Down-$0.15 (-6.82%)
Updated Sep 10, 2026, 4:34 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PALI closed at $2.05 after 20 trading sessions, up 4.59% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $2.17 | $2.21 | $2.05 | $2.05 | 2.77M |
| Sep 8, 2026 | $2.09 | $2.235 | $2.08 | $2.20 | 3.53M |
| Sep 4, 2026 | $2.03 | $2.12 | $2.00 | $2.09 | 1.76M |
| Sep 3, 2026 | $2.01 | $2.05 | $1.97 | $2.045 | 1.09M |
| Sep 2, 2026 | $1.96 | $2.005 | $1.95 | $1.99 | 731.45K |
| Sep 1, 2026 | $1.96 | $1.98 | $1.915 | $1.96 | 879.45K |
| Aug 31, 2026 | $2.02 | $2.02 | $1.93 | $1.95 | 1.65M |
| Aug 28, 2026 | $2.10 | $2.1116 | $1.99 | $2.00 | 2.13M |
| Aug 27, 2026 | $2.12 | $2.16 | $2.095 | $2.11 | 899.22K |
| Aug 26, 2026 | $2.06 | $2.135 | $2.032 | $2.13 | 1.19M |
| Aug 25, 2026 | $2.02 | $2.10 | $1.98 | $2.07 | 2.07M |
| Aug 24, 2026 | $2.10 | $2.10 | $2.00 | $2.01 | 1.62M |
| Aug 21, 2026 | $2.09 | $2.135 | $2.08 | $2.10 | 1.07M |
| Aug 20, 2026 | $2.14 | $2.15 | $2.03 | $2.06 | 1.32M |
| Aug 19, 2026 | $2.10 | $2.19 | $2.085 | $2.16 | 2.29M |
| Aug 18, 2026 | $2.15 | $2.15 | $2.01 | $2.04 | 2.29M |
| Aug 17, 2026 | $2.13 | $2.22 | $2.10 | $2.15 | 1.4M |
| Aug 14, 2026 | $2.12 | $2.15 | $2.06 | $2.14 | 1.61M |
| Aug 13, 2026 | $1.99 | $2.15 | $1.98 | $2.15 | 2.47M |
| Aug 12, 2026 | $2.14 | $2.18 | $1.95 | $1.96 | 2.38M |
The latest Smart Investors Daily articles mentioning PALI.
PALI research
Company profile and research snapshot.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 23, 2026 | Oppenheimer | Outperform | — |
| Apr 9, 2026 | Wolfe Research | Outperform | — |
| Mar 26, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 25, 2026 | Stifel | Buy | — |
| Jan 9, 2026 | B. Riley Securities | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 9, 2026
U.S. futures were mixed; ServiceTitan plunged 16.7% on weak Q3 guidance, while Mind Technology, Braze and others also fell premarket.
Yahoo · Sep 3, 2026
Denver, CO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that members of management will participate in three healthcare investor conferences in September 2026. Wells Fargo 2026 Healthcare Conference Dates: September 8–10, 2026Location: Boston, MassachusettsFormat: Investor meetings Morga
Benzinga · Aug 10, 2026
Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 91.38 percent increase over losses of $(0.58) per share from the same period last year. The
Benzinga · Jul 23, 2026
Analyst initiates a Buy rating on Palisade Bio with an $8 target, highlighting PALI-2108's multi-billion dollar potential in IBD treatment.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PALI.
